TherapeuticsMD Inc (NASDAQ:TXMD) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 69,651,906 shares, a growth of 4.4% from the October 15th total of 66,719,902 shares. Based on an average daily volume of 3,686,691 shares, the days-to-cover ratio is currently 18.9 days. Approximately 36.5% of the shares of the company are sold short.
In other TherapeuticsMD news, CEO Robert G. Finizio sold 184,000 shares of the firm’s stock in a transaction on Friday, September 7th. The stock was sold at an average price of $6.24, for a total transaction of $1,148,160.00. Following the completion of the sale, the chief executive officer now owns 18,485,559 shares of the company’s stock, valued at approximately $115,349,888.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Brian Bernick sold 182,800 shares of the firm’s stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $6.30, for a total value of $1,151,640.00. Following the sale, the director now directly owns 242,000 shares of the company’s stock, valued at approximately $1,524,600. The disclosure for this sale can be found here. Insiders have sold a total of 2,158,800 shares of company stock valued at $12,946,562 in the last ninety days. Insiders own 22.85% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Fox Run Management L.L.C. acquired a new position in TherapeuticsMD in the second quarter valued at about $121,000. Managed Account Services Inc. acquired a new position in TherapeuticsMD in the third quarter valued at about $117,000. Affiance Financial LLC acquired a new position in TherapeuticsMD in the second quarter valued at about $156,000. Twin Focus Capital Partners LLC acquired a new position in TherapeuticsMD in the second quarter valued at about $187,000. Finally, Xact Kapitalforvaltning AB raised its stake in TherapeuticsMD by 96.3% in the first quarter. Xact Kapitalforvaltning AB now owns 31,800 shares of the company’s stock valued at $155,000 after purchasing an additional 15,600 shares in the last quarter. 66.20% of the stock is owned by institutional investors and hedge funds.
TXMD has been the subject of a number of research reports. Oppenheimer set a $14.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday. Zacks Investment Research raised TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Friday, November 2nd. BidaskClub downgraded TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Thursday, November 1st. ValuEngine downgraded TherapeuticsMD from a “buy” rating to a “hold” rating in a report on Monday, October 29th. Finally, Cantor Fitzgerald set a $27.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a report on Monday, October 29th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. TherapeuticsMD currently has an average rating of “Buy” and an average target price of $13.45.
TXMD opened at $4.93 on Friday. TherapeuticsMD has a fifty-two week low of $4.30 and a fifty-two week high of $7.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 7.88 and a quick ratio of 7.79. The firm has a market cap of $1.09 billion, a PE ratio of -13.32 and a beta of 1.40.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Wednesday, November 7th. The company reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.06. The business had revenue of $3.47 million during the quarter, compared to the consensus estimate of $4.43 million. TherapeuticsMD had a negative return on equity of 80.75% and a negative net margin of 582.86%. TherapeuticsMD’s revenue for the quarter was down 21.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.07) earnings per share. On average, sell-side analysts predict that TherapeuticsMD will post -0.63 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Short Interest in TherapeuticsMD Inc (TXMD) Increases By 4.4%” was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/11/10/short-interest-in-therapeuticsmd-inc-txmd-increases-by-4-4.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
See Also: Stop Order
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.